News Conference News ESC 2019 Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints Todd Neale September 11, 2019
News Conference News ESC 2019 LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17 Todd Neale September 10, 2019
News Conference News ESC 2019 TRANSIENT: Treatment Timing Inconsequential When STEMI Resolves Before Revascularization L.A. McKeown September 09, 2019
News Conference News ESC 2019 AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD Todd Neale September 02, 2019
News Conference News ESC 2019 COMPLETE Beats Culprit-Only PCI in Multivessel STEMI and Timing Doesn’t Matter Yael L. Maxwell September 01, 2019